Facebook Twitter LinkedIn Google Plus RSS

J&J buys California pharma firm in deal worth up to $1B

By

A New Jersey pharmaceutical giant will spend up to $1 billion to boost its prostate cancer portfolio.

New Brunswick-based Johnson & Johnson said Monday it will purchase Aragon Pharmaceuticals Inc., a California-based drug company focused on developing treatments for hormone-dependent cancers. The sale includes $650 million in cash upfront, with a possibility of up to $350 million in future milestone payments.

Under the deal, Johnson & Johnson will take Aragon’s androgen receptor antagonist program. The rest of the company’s assets will be spun off into a new company, which J&J won’t own.

Aragon’s lead androgen receptor antagonist product is a treatment for castration-resistant prostate cancer. The drug candidate, known as ARN-509, is currently in Phase 2 development.

In a statement, Dr. Peter F. Lebowitz, global therapeutic area head for oncology at J&J’s Janssen Research & Development LLC, said the deal strengthens the company’s prostate cancer drug development portfolio. He said it complements Johnson & Johnson’s highly successful prostate cancer drug Zytiga, which had $344 million in sales during the first quarter of the year.

“Prostate cancer is one of our main areas of focus, and we are pleased to be adding ARN-509 to our portfolio,” Lebowitz said, in a press release.

The deal already has been approved by the boards of both J&J and Aragon, but is still subject to regulatory approval. Johnson & Johnson expects the deal to close in the third quarter of this year.

Write to the Editorial Department at editorial@njbiz.com

Leave a Comment

test

Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy

Comments

close
Subscribe to Our Newsletters!
Click Here to Subscribe for Free Now!